EVOKE PHARMA INC's ticker is EVOK and the CUSIP is 30049G104. A total of 10 filers reported holding EVOKE PHARMA INC in Q2 2014. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $110,000 | -6.0% | 222,948 | +6.1% | 0.00% | – |
| Q4 2021 | $117,000 | -61.5% | 210,102 | -10.3% | 0.00% | – |
| Q3 2021 | $304,000 | +13.4% | 234,309 | +19.7% | 0.00% | – |
| Q2 2021 | $268,000 | -8.2% | 195,760 | +22.4% | 0.00% | – |
| Q1 2021 | $292,000 | -29.1% | 159,979 | 0.0% | 0.00% | – |
| Q4 2020 | $412,000 | -42.9% | 159,979 | +3.9% | 0.00% | – |
| Q3 2020 | $722,000 | +8.2% | 154,039 | -18.3% | 0.00% | – |
| Q2 2020 | $667,000 | +182.6% | 188,514 | -7.6% | 0.00% | – |
| Q1 2020 | $236,000 | -63.9% | 204,051 | -49.6% | 0.00% | – |
| Q4 2019 | $654,000 | +282.5% | 404,536 | +102.6% | 0.00% | – |
| Q3 2019 | $171,000 | +155.2% | 199,678 | +86.0% | 0.00% | – |
| Q2 2019 | $67,000 | +97.1% | 107,361 | +365.8% | 0.00% | – |
| Q1 2019 | $34,000 | -70.2% | 23,048 | -50.0% | 0.00% | – |
| Q4 2018 | $114,000 | +67.6% | 46,096 | +100.0% | 0.00% | – |
| Q3 2018 | $68,000 | +19.3% | 23,048 | 0.0% | 0.00% | – |
| Q2 2018 | $57,000 | +21.3% | 23,048 | 0.0% | 0.00% | – |
| Q1 2018 | $47,000 | -9.6% | 23,048 | 0.0% | 0.00% | – |
| Q4 2017 | $52,000 | -31.6% | 23,048 | 0.0% | 0.00% | – |
| Q3 2017 | $76,000 | +28.8% | 23,048 | 0.0% | 0.00% | – |
| Q2 2017 | $59,000 | -16.9% | 23,048 | 0.0% | 0.00% | – |
| Q1 2017 | $71,000 | +121.9% | 23,048 | +45.3% | 0.00% | – |
| Q4 2016 | $32,000 | -8.6% | 15,864 | 0.0% | 0.00% | – |
| Q3 2016 | $35,000 | -67.6% | 15,864 | 0.0% | 0.00% | – |
| Q2 2016 | $108,000 | +35.0% | 15,864 | 0.0% | 0.00% | – |
| Q1 2016 | $80,000 | +53.8% | 15,864 | 0.0% | 0.00% | – |
| Q4 2015 | $52,000 | +13.0% | 15,864 | 0.0% | 0.00% | – |
| Q3 2015 | $46,000 | -43.9% | 15,864 | 0.0% | 0.00% | – |
| Q2 2015 | $82,000 | -26.1% | 15,864 | 0.0% | 0.00% | – |
| Q1 2015 | $111,000 | +19.4% | 15,864 | 0.0% | 0.00% | – |
| Q4 2014 | $93,000 | +66.1% | 15,864 | +54.4% | 0.00% | – |
| Q3 2014 | $56,000 | -30.0% | 10,276 | 0.0% | 0.00% | – |
| Q2 2014 | $80,000 | -5.9% | 10,276 | 0.0% | 0.00% | – |
| Q1 2014 | $85,000 | – | 10,276 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 242,500 | $1,962,000 | 1.69% |
| SOPHROSYNE CAPITAL LLC | 49,000 | $397,000 | 0.40% |
| LMR Partners LLP | 23,882 | $187,000 | 0.02% |
| GEODE CAPITAL MANAGEMENT, LLC | 10,276 | $80,000 | 0.00% |
| BlackRock Investment Management, LLC | 489 | $4,000 | 0.00% |
| MORGAN STANLEY | 500 | $4,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 84 | $1,000 | 0.00% |
| VANGUARD GROUP INC | 48,394 | $378,000 | 0.00% |
| UBS AG | 727 | $6,000 | 0.00% |
| BANK OF AMERICA CORP /DE/ | 33,500 | $271,000 | 0.00% |